研究方向：

主要研究方向为化学生物学和结构生物学研究。包括基于靶标的药物筛选、与疾病有关靶标的结构、药物作用机制研究及基于结构生物学的创新药物设计。

简历：

2008年7月毕业于中科院福建物质结构研究所获博士学位

2008年8月至2011年7月在德国吕贝克大学生物化学系做博士后研究，研究内容：抗病毒药物筛选及病毒重要靶标的结构生物学研究

2011年8月至今在华东理工大学药学院任副教授，研究内容：1. 药物筛选和新药发现; 2. 药物靶标确证; 3. 生物芯片研制及应用

联系方式：

电话：021-64253379.  email：zhulfl@ecust.edu.cn

所获荣誉：

u  2012年校首批优秀青年教师培育计划

u  2015年校优秀青年教师培育跟踪计划

u  2019年校青年英才培育计划

代表性研究成果：

10篇代表性期刊论文

1)        Lili Zhu; Lei Shan; Junsheng Zhu; Li Li; Shiliang Li; Liyan Wang; Jiawei Wang; Shoude Zhang; Hongchang Zhou; Weidong Zhang; Honglin Li; Discovery of a natural fluorescent probe targeting the Plasmodium falciparum cysteine protease falcipain-2, SCIENCE CHINA Life Sciences, 2020, 63: 1016-1025      (第一作者，IF=6.036)

2)        Guozhen Wu^#; Lili Zhu^#; Xing Yuan; Hao Chen; Rui Xiong; Shoude Zhang; Hao Cheng; Yunheng Shen; Huazhang An; Tiejun Li; Honglin Li; Weidong Zhang ; Britanin Ameliorates Cerebral Ischemia-Reperfusion Injury by Inducing the Nrf2 Protective Pathway, ANTIOXIDANTS & REDOX SIGNALING, 2017, 27(11): 754-768      (第一作者，IF=8.401)

3)        Yi Tong; Qian Jiao; Yuanru Liu; Jiankun Lv; Rui Wang; Lili Zhu; Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats, Frontiers in Pharmacology, 2018, 9: 0-1032     (通讯作者，IF=5.811)

4)        Jiawei Wang; Yanyan Diao; Junsheng Zhu; Shiliang Li; Zhenjiang Zhao; Honglin Li; Lili Zhu ; Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase, Medchemcomm, 2016, 7(5): 853-858     (通讯作者，IF=3.597)

5)        Fangshu Wu; Junsheng Zhu; Honglin Li; Lili Zhu; Structural analysis of recombinant human ubiquitin-conjugating enzymeUbcH5c, Acta Pharmaceutica Sinica B, 2017, 7(3): 390-394      (通讯作者，IF=11.614)

6)        Junsheng Zhu; Le Han; Yanyan Diao; Xiaoli Ren; Minghao Xu; Liuxin Xu; Shiliang Li; Qiang Li; Dong Dong; Jin Huang; Xiaofeng Liu; Zhenjiang Zhao; Rui Wang; Lili Zhu*; Yufang Xu*; Xuhong Qian*; Honglin Li*;Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase, Journal of Medicinal Chemistry, 2015, 58:1123−1139   (通讯作者，IF=7.446)

7)        Minghao Xu; Junsheng Zhu; Yanyan Diao; Hongchang Zhou; Xiaoli Ren; Deheng Sun; Jin Huang; Dongmei Han; Zhenjiang Zhao; Lili Zhu*; Yufang Xu*; Honglin Li*; Novel Selective and Potent Inhibitors of Malaria Parasite Dihydroorotate Dehydrogenase: Discovery and Optimization of Dihydrothiophenone Derivatives, Journal of Medicinal Chemistry, 2013, 56: 7911−7924   (通讯作者，IF=7.446)

8)        Fanxun Zeng; Shiliang Li; Guantian Yang; Yating Luo; Tiantian Qi; Yingfan Liang; Tingyuan Yang; Letian Zhang; Rui Wang; Lili Zhu*; Honglin Li*; Xiaoyong Xu*; Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis, Acta Pharmaceutica Sinica B, 2021,11:795-809  (通讯作者，IF=11.614)

9)        Pengxuan Ren; Weijuan Shang; Wanchao Yin; Huan Ge; Lin Wang; Xianglei Zhang; Bingqian Li; Honglin Li; Yechun Xu; Eric H. Xu; Hualiang Jiang; Lili Zhu*; Leike Zhang*; Fang Bai*; A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors, Acta pharmacologica Sinica, 2022;43(2):483-493  (通讯作者，IF=6.15)

10)    Lin Wang, Yan Wu, Sheng Yao, Huan Ge, Ya Zhu, Kun Chen, Wenzhang Chen, Yi Zhang, Wei Zhu, Hong-yang Wang, Yu Guo, Peixiang Ma, Peng-xuan Ren, Xiang-lei Zhang, Huiqiong Li, Mohammad A. Ali, Wenqing Xu, Hua-liang Jiang, Leike Zhang, Lili Zhu*, Yang Ye*, Weijuan Shang*, Fang Bai*;Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Acta pharmacologica Sinica, 2021;1-9   (通讯作者，IF=6.15)

专利

u  授权专利：ZL 2012 80048338.3；ZL201510319723.2; ZL201810075170.4